Sort   by:  
 Page size 
TranscriptomicsA chemical genetic approach identifies piperazine antipsychotics as promoters of CNS neurite growth on inhibitory substrates.
Injury to the central nervous system (CNS) may result in lifelong loss of function due, in part, to the regenerative failure of CNS neurons. Major barriers to regeneration faced by injured CNS neurons include inhibitory proteins derived from myelin and the astroglial scar. Previously, we described...
ORGANISM(S): Homo sapiens 
2012-04-29 | E-GEOD-34331 | biostudies-arrayexpress
MetabolomicsMetabolomics of Metabolic Risk in Patients Taking Atypical Antipsychotics (part II)
Not available
ORGANISM(S): Homo sapiens 
ST001098 | MetabolomicsWorkbench
MetabolomicsMetabolomics of Metabolic Risk in Patients Taking Atypical Antipsychotics (part I)
Not available
ORGANISM(S): Homo sapiens 
ST001097 | MetabolomicsWorkbench
MetabolomicsExamining the Identified Differential Metabolites in Other Antipsychotics with a High Fatality Frequency
Not available
ORGANISM(S): Mus musculus 
ST001746 | MetabolomicsWorkbench
MetabolomicsExamining the Identified Differential Metabolites in Other Antipsychotics with a High Fatality Frequency (part IV)
Not available
ORGANISM(S): Mus musculus 
ST001782 | MetabolomicsWorkbench
ProteomicsBiochemical Pathways Triggered by Antipsychotics in Human Oligodendrocytes: Potential of Discovering New Treatment Targets
Schizophrenia is a psychiatric disorder that affects more than 21 million people worldwide. It is an incurable disorder and the primary means of managing symptoms is through administration of pharmacological treatments, which consist heavily of antipsychotics. First-generation antipsychotics have th...
ORGANISM(S): Homo sapiens (Human) 
2019-11-12 | PXD008892 | Pride
Proteomics Quetiapine Mechanism of action Haloperidol Schizophrenia Chlorpromazine Risperidone Biomarkers 
Genomics
Antipsychotics and the Microbiome
PRJNA1445182 | ENA
ProteomicsA snapshot of blood plasma proteomics in clinical response to atypical antipsychotics in schizophrenia – An exploratory study
Antipsychotics are usually the first option to treat schizophrenia; however, for a considerable fraction of patients, it lacks efficacy. Furthermore, there are no known biomarkers to indicate a treatment’s efficacy in a patient. Schizophrenia causes a large socioeconomic burden on countries along wi...
ORGANISM(S): Homo sapiens (Human) 
2020-06-01 | PXD015213 | Pride
Proteomics Blood plasma Mass spectrometry Schizophrenia Antipsychotics Risperidone Olanzapine. 
ProteomicsProteomic landscape of atypical antipsychotics clinical response in blood plasma from schizophrenia patients
Antipsychotics are the main line of treatment for schizophrenia, despite being effective only in about 50% of patients. Additionally, serious side effects may cause medication drop-out, aggravated by a lack of understanding about how these drugs act at molecular level. As proteomics is a suitable...
ORGANISM(S): Homo sapiens (Human) 
2020-06-01 | PXD015049 | Pride
Proteomics Blood plasma Mass spectrometry Olanzapine Risperidone Schizophrenia Antipsychotics 
GenomicsEffects of antipsychotics risperidone and olanzapine on the striatum, liver, pancreas and adipose tissue
Effects of antipsychotics risperidone and olanzapine on the striatum, liver, pancreas and adipose tissue
PRJNA748379 | ENA
Sort   by:  
 Page size